Frequency Therapeutics Inc. (FREQ)
$0.30
$-13.84
(-97.88%)
As on 03-Nov-2023 16:00EDT
Market cap
$11 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
0.9
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-1 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-0.2
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-1.7
-
Face value
--
-
Shares outstanding
36,520,800
6 Years Aggregate
CFO
$-176.91 Mln
EBITDA
$-240.50 Mln
Net Profit
$-248.19 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Frequency Therapeutics (FREQ)
| -99.8 | -98.4 | -99.0 | -99.7 | -93.4 | -- | -- |
|
BSE Sensex*
| -8.7 | 3.6 | -7.5 | -4.2 | 8.2 | 9.5 | 11.9 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2022
|
2021
|
2020
|
|---|---|---|---|
|
Frequency Therapeutics (FREQ)
| -25.0 | -85.5 | 101.1 |
|
S&P Small-Cap 600
| -17.4 | 25.3 | 9.6 |
|
BSE Sensex
| 4.4 | 22.0 | 15.8 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Frequency Therapeutics (FREQ)
|
0.3 | 10.9 | 0.0 | -59.3 | -- | -131.8 | -- | 0.9 |
| 2.8 | 119.6 | 0.0 | -57.7 | -- | -40.8 | -- | 0.3 |
Shareholding Pattern
View DetailsAbout Frequency Therapeutics (FREQ)
As of November 3, 2023, Frequency Therapeutics, Inc. was acquired by Korro Bio, Inc., in a reverse merger transaction. Frequency Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics to activate a person's... innate regenerative potential to restore function. Its Progenitor Cell Activation approach uses small molecules to activate progenitor cells within the body to create functional tissue. The company's lead product candidate is FX-322, which is in Phase IIb clinical trial to treat the underlying cause of sensorineural hearing loss. It is also developing medicines for patients across a range of degenerative conditions, including multiple sclerosis, and diseases of the muscle, gastrointestinal tract, skin, and bone. The company has a license and collaboration agreement with Astellas Pharma Inc. for the development and commercialization of FX-322, as well as collaboration and licensing agreements with Massachusetts Eye and Ear, the Massachusetts Institute of Technology, and The Scripps Research Institute. Frequency Therapeutics, Inc. was incorporated in 2014 and is headquartered in Lexington, Massachusetts. Read more
-
Co-Founder, Pres, CEO & Director
Mr. David L. Lucchino
-
Co-Founder, Pres, CEO & Director
Mr. David L. Lucchino
-
Headquarters
Lexington, MA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Frequency Therapeutics (FREQ)
What is the current share price of Frequency Therapeutics Inc (FREQ) Today?
The share price of Frequency Therapeutics Inc (FREQ) is $0.30 (NASDAQ) as of 03-Nov-2023 16:00 EDT. Frequency Therapeutics Inc (FREQ) has given a return of -93.43% in the last 3 years.
What is the current PB & PE ratio of Frequency Therapeutics Inc (FREQ)?
Since, TTM earnings of Frequency Therapeutics Inc (FREQ) is negative, P/E ratio is not available.
The P/B ratio of Frequency Therapeutics Inc (FREQ) is 0.91 times as on 16-Nov-2023, a 79 discount to its peers’ median range of 4.42 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2022
|
-1.66
|
-0.52
|
|
2021
|
-2.10
|
1.36
|
|
2020
|
-44.96
|
-12.50
|
|
2019
|
-31.12
|
-7.23
|
|
2018
|
--
|
--
|
What is the 52 Week High and Low of Frequency Therapeutics Inc (FREQ)?
The 52-week high and low of Frequency Therapeutics Inc (FREQ) are Rs -- and Rs -- as of 09-May-2026.
What is the market cap of Frequency Therapeutics Inc (FREQ)?
Frequency Therapeutics Inc (FREQ) has a market capitalisation of $ 11 Mln as on 16-Nov-2023. As per SEBI classification, it is a Small Cap company.
Should I invest in Frequency Therapeutics Inc (FREQ)?
Before investing in Frequency Therapeutics Inc (FREQ), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.